Executive Vice President & Chief Scientific Officer & Global Head BD&L

Sr. Human Resources Business Partner

Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026

WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement

WuXi Biologics Recognized by Hong Kong ESG Reporting Awards 2025 for Outstanding ESG Disclosure

WuXi Biologics Achieves CDP Highest "A" Ratings in Both Climate Change and Water Security

Director - Executive Director, CMC

WuXi Biologics is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics. The Director - Executive Director, CMC will provide project leadership for IND enabling and late-stage product development CMC activities, ensuring successful execution of projects and alignment with regulatory requirements.

Chief Financial Officer

Chief Business Officer

5 Stock Picks Last Week From Wall Street's Most Accurate Analysts

Chutes & Ladders—Metabolic marketing master maneuvers to CEO

Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications

Centessa Pharmaceuticals plc appoints Mario Alberto Accardi as CEO

Executive Director, Regulatory CMC

Centessa Pharmaceuticals plc is a new kind of pharmaceutical company with a focus on data-driven decision-making and an asset-centric R&D model. The Executive Director, Regulatory CMC will lead global CMC regulatory activities, ensuring compliance with health authorities and driving regulatory strategies throughout drug development and lifecycle management.

Executive Director and Chairman

HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HUTCHMED stock rises after sovleplenib meets primary endpoint in Phase III trial

Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026

HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma

Director - Executive Director, Regulatory Affairs, CMC

HUTCHMED is focused on developing innovative global registration strategies for their pipeline. The Regulatory Affairs CMC Director/Senior Director/Executive Director will lead the international Regulatory Affairs CMC team and support the development of global CMC regulatory registration strategies for successful approval of biologics and chemical drug products.

Senior/Executive Director Regulatory CMC

Vivid Resourcing is an innovative and fast-growing biopharmaceutical company based in Boston, seeking a Senior/Executive Director, Regulatory CMC to lead global Chemistry, Manufacturing & Controls (CMC) regulatory strategy. The role involves designing and executing global CMC regulatory strategies, overseeing submissions, and engaging with health authorities while collaborating across various departments.

Executive/Senior Director Regulatory CMC

Senior Vice President, Regeneron Pharmaceuticals, General Manager, Regeneron Genetics Center

Senior Vice President, Head Development Operations & Portfolio Management

Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity

2025 drug approvals: Despite FDA tumult and macro uncertainty, biopharma scored with 55 new products

Regeneron Just Moved From Underperform To Buy - Here's Why

300 Exceptional Teen Scientists Recognized for Innovative STEM Research in Nation’s Oldest and Most Prestigious High School Competition

Executive Director, CMC Program Management (Biology)

Regeneron is hiring an Executive Director to lead operations and program management for a diverse portfolio of biology-based advanced therapies. The role involves overseeing cross-functional execution from early development through commercialization, ensuring timely supply and regulatory readiness.

CEO, Skeletal Dysplasias (QED Therapeutics)

CEO and Founder

BridgeBio to Participate in the J.P. Morgan Healthcare Conference

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio presents BBO-10203 data at San Antonio Breast Cancer Symposium

Sustained drop in all-cause mortality observed with BridgeBio’s acoramidis

0.6666666865348816

Executive Director, U.S. Public Policy

BridgeBio is a pioneering company in the biotech sector focused on developing life-changing medicines for patients with unmet needs. The Executive Director, U.S. Public Policy will lead the public policy strategy related to Medicare, Medicaid, and payment models, advising executive leadership and shaping policy positions that influence access and reimbursement.

Executive Director, U.S. Public Policy (CMS, HHS & Payment Policy)

Director   Executive Director, Cmc